Multi-modality imaging in transthyretin amyloid cardiomyopathy

Bryan Paul Traynor, Aamir Shamsi, Victor Voon

Abstract

Transthyretin amyloid (TTR) cardiomyopathy is a disease of insidious onset, which is often accompanied by debilitating neurological and/or cardiac complications. The true prevalence is not fully known due to its elusive presentation, being often under-recognized and usually diagnosed only late in its natural history and in older patients. Because of this, effective treatment options are usually precluded by multiple comorbidities and frailty associated with such patients. Therefore, high clinical suspicion with earlier and better detection of this disease is needed. In this review, the novel applications of multimodality imaging in the diagnostic pathway of TTR cardiomyopathy are explored. These include the complimentary roles of transthoracic echocardiography, cardiac magnetic resonance, nuclear scintigraphy and positron emission tomography in quantifying cardiac dysfunction, diagnosis and risk stratification. Recent advances in novel therapeutic options for TTR have further enhanced the importance of a timely and accurate diagnosis of this disease.

Key words: Multimodality imaging; Cardiac amyloidosis; Transthyretin; Echocardiography; Cardiac magnetic resonance; Nuclear imaging
INTRODUCTION

Transthyretin amyloid (TTR) cardiomyopathy is a disease characterized by extracellular accumulation of abnormal amyloid protein fibrils due to autosomal dominant hereditary mutation transmission or from a wild type (acquired) form, previously referred to as senile amyloidosis. Transthyretin is a protein primarily synthesized in the liver and can dissociate, subsequently aggregating to produce amyloid. Distinctively, TTR cardiomyopathy lies in one part of the spectrum of amyloid cardiomyopathy compared to primary systemic amyloidosis or light-chain amyloid (AL) cardiomyopathy, often due to plasma cell dyscrasia.

However, amyloid cardiomyopathy, particularly the TTR subtype, is often under-diagnosed, as patients are often asymptomatic or present with nonspecific symptoms early in the trajectory of the disease. Although certain electrocardiographic markers (i.e., low voltage QRS) may suggest the presence of amyloid cardiomyopathy, these markers are not specific, particularly for TTR. Left ventricular (LV) hypertrophy criteria on electrocardiography has only been observed in 25% of TTR cardiomyopathy. While biomarkers such as natriuretic peptides and troponin may be elevated in TTR cardiomyopathy, inferring worse prognosis, their utility in diagnosis of the disease is limited. The diagnostic yield is further challenged by the utility of the gold standard of endomyocardial biopsy, which may be limited by sampling errors in early disease and false positive/negative rates of approximately 10%.

Therefore, the true prevalence of TTR cardiomyopathy is not fully known as it is usually diagnosed late in its natural history when the disease is well established. Previous reports using imaging and histological evidence have estimated TTR cardiomyopathy prevalence to be between 0.36% to 25% in different cohorts of elderly patients, including those with aortic stenosis and heart failure with preserved ejection fraction. These have been associated with worse outcomes. With that, these observations support the need for higher clinical suspicion and earlier screening and diagnosis of TTR cardiomyopathy with non-invasive imaging modalities.

Indeed, the timely detection of TTR cardiomyopathy may allow earlier implementation of disease-modifying therapy, improving survival. Conventionally, orthotopic liver and/or heart transplantation has been offered to these patients as possible curative treatments, as the misfolded TTR protein is synthesized in the liver. Advanced age at liver transplantation and duration of disease have been associated with increased mortality. Patients are also more likely to be suitable surgical candidates at earlier stages of the disease. Furthermore, recent studies have demonstrated beneficial outcomes in patients with TTR treated with novel medical therapies. Published data from the ATTR-ACT trial has shown significant reductions in all-cause mortality in TTR-diagnosed patients treated with Tafamidis, a novel agent with TTR stabilizing properties, along with improvements in cardiovascular-related hospitalizations and quality of life measurements. The authors of this study speculate that treatment with this agent early in the disease course will convey greater benefit, similar to its effect in TTR familial amyloid neuropathy. In a subpopulation of the APOLLO study, the RNA inhibitor, Patisaran, has shown statistically significant improvements in certain exploratory endpoints measuring cardiac function, including natriuretic peptide levels, LV wall thickness and global longitudinal strain. These therapeutic options offer promising solutions and support the need for a timely diagnosis. Otherwise, TTR cardiomyopathy is commonly associated with long-term debilitating neurological and cardiac complications such as arrhythmias and heart failure.

With that, this focused review aims to highlight the role of multimodality imaging in the diagnosis and risk stratification of patients with TTR cardiomyopathy.
TRANSTHORACIC ECHOCARDIOGRAPHY

Echocardiography is the primary initial imaging modality performed in the investigation of amyloid cardiomyopathy when clinically suspected. While it is a widely available and inexpensive imaging modality, its ability to differentiate between amyloid cardiomyopathy subtypes is limited and when amyloid cardiomyopathy is suspected based on echocardiography, further investigations are necessary to confirm TTR cardiomyopathy.

Increased LV wall thickness, particularly in the absence of high electrocardiographic voltages, and diastolic dysfunction are among the common early echocardiographic features seen which can raise suspicion of amyloid cardiomyopathy, although the differentials for such features are wide.[18-21]. In the later stages of the disease, a restrictive filling pattern and bialtrial dilatation may be accompanied by pleural and/or pericardial effusions.[22-24]. Although not highly specific, LV wall thickness tends to increase to a greater degree in TTR compared to AL cardiomyopathy.[25]

Using myocardial strain analysis, the presence of relative apical sparing of longitudinal strain is very characteristic of amyloid cardiomyopathy and has been demonstrated as a reproducible method of accurately differentiating amyloid cardiomyopathy from other causes of LV hypertrophy. In a study comparing 55 patients with amyloid cardiomyopathy to 30 patients with LV hypertrophy due to either hypertrophic cardiomyopathy or aortic stenosis, the presence of relative apical longitudinal strain was 93% sensitive and 82% specific in identifying amyloid cardiomyopathy.[26]. This apical sparing pattern of global circumferential strain is usually observed unless severe diastolic dysfunction is present.[27]. Furthermore, this imaging technique may better aid the identification of amyloid cardiomyopathy in challenging patient subgroups with mild LV wall thickening and preserved ejection fraction.[28]. Despite that, there is limited data on echocardiographic features specific to TTR cardiomyopathy. In a study of biopsy-proven TTR patients using speckle-tracking echocardiography, acquired TTR was characterized by lower LV ejection fraction, as well as lower basal and mid LV radial strain compared to inherited TTR.[29]. In addition, only few echocardiographic markers have demonstrated prognostic value specific to TTR cardiomyopathy. Among these, impairment of left atrial function, using conventional and strain-derived speckle-tracking parameters, has been demonstrated in amyloid cardiomyopathy and closely correlates to LV deformation. Acquired TTR was associated with worse left atrial function when compared to inherited TTR or AL.[30]. In terms of strain imaging, 4-chamber longitudinal strain was significantly associated with major adverse cardiovascular events in amyloid cardiomyopathy, superior to traditional parameters.[31]. Relative apical sparing pattern of global longitudinal strain may indicate worse prognosis, particularly when combined with low LV ejection fraction.[32]. In assessing the right ventricle, TAPSE can independently predict major adverse events in amyloid cardiomyopathy patients.[33]. Right ventricular dilatation has also been associated with more severe cases of amyloid cardiomyopathy and infers very poor prognosis.[34].

BONE SCINTIGRAPHY

In 1975, $^{99m}$Tc-methylene diphosphonate accumulation in amyloid cardiomyopathy was reported for the first time.[35]. Since then, multiple bone scintigraphy tracers have been tested, although their cellular binding mechanisms are not fully known. Several of these tracers have been predominantly utilized and are described below. Scintigraphy tracer uptake in TTR cardiomyopathy has been suggested as possibly due to the increased number of small microcalcifications seen in the myocardium in TTR.[36]. The presence of cardiac tracer uptake confirms amyloid cardiomyopathy but has not been able to exclusively differentiate TTR cardiomyopathy from other subtypes. In addition, the absence of tracer uptake does not rule out amyloid cardiomyopathy.

The authors of a large study of 1217 patients that underwent radionuclide scintigraphy, either $^{99m}$Tc-Technetium-3,3-diphosphono-1,2-propanodicarboxylic acid ($^{99m}$Tc-DPD), $^{99m}$Tc-Technetium or pyrophosphate ($^{99m}$Tc-PYP) or $^{99m}$Tc-hydroxymethylene diphosphonate ($^{99m}$Tc-HMDP) proposed a non-invasive diagnostic criteria for TTR cardiomyopathy.[37]. TTR was suggested by a score of 2 or 3 with the use of the Perugini visual score of myocardial radiotracer enhancement (Table 1). Grade 2 or 3 enhancement was shown to be 90% sensitive and 97% specific for TTR cardiomyopathy using this scoring system. Furthermore, when grade 2 or 3 uptake is...
combined with absence of monoclonal proteins in serum or urine testing, the diagnostic accuracy improves further. A specificity and positive predictive value of 100% has been demonstrated in this regard. This was consistent among all three of the radiotracers used in the study.

Interestingly, while absence of abnormal cardiac uptake of radionuclide tracer confers a prognostic benefit, Perugini grade stratification at diagnosis has yet to show prognostic significance in TTR cardiomyopathy[34]. These observations are further supported by a study of a large cohort of patients undergoing scintigraphy for non-cardiac reasons. Of 12521 patients included, myocardial tracer uptake was demonstrated in 0.36%[34].

Despite the added value of nuclear scintigraphy in the diagnostic pathway of amyloid cardiomyopathy, there remains low penetrance and high variability in its utilization[35], thus indicating a greater need for standardization in technique between centres.

**99mTc-DPD scintigraphy**

99mTc-DPD scintigraphy is a highly sensitive technique for imaging TTR cardiomyopathy. In a study utilizing 99mTc-DPD scintigraphy, all 158 patients with TTR and clinical cardiac involvement demonstrated cardiac tracer uptake[36]. In the diagnosis of TTR cardiomyopathy, a study comparing 15 patients with TTR cardiomyopathy to 10 patients with AL-related cardiomyopathy revealed both sensitivity and specificity of 100% in identifying the TTR cohort using 99mTc-DPD scintigraphy[37]. Another more recent study comparing a larger group of 45 patients with TTR cardiomyopathy to 34 with AL cardiomyopathy and 15 controls again showed high levels of accuracy with positive and negative predictive values of 88% and 100% using a visual score of ≥ 2[38]. 99mTc-DPD use as a modality in diagnosing and differentiating TTR from AL cardiomyopathy has also been supported by a study of a small Australian cohort of 13 TTR patients, all showing diagnostic tracer uptake, while 25% of patients with AL-related cardiac involvement showed uptake[39].

99mTc-DPD has been observed to distribute predominantly in the cardiac septal and basal segments and lowest uptake is found in the apical and apico-antero-lateral segments[40].

Furthermore, reasonable intermodality agreement 99mTc-DPD has been shown with cardiac magnetic resonance (CMR) in the identification of TTR cardiomyopathy. Significantly improved estimation of cardiac involvement was seen using 99mTc-DPD scintigraphy when compared to late gadolinium enhancement (LGE) on CMR in a study of 18 patients diagnosed with TTR. These consecutively diagnosed patients had a mean age of 50 years, 56% were female and 56% were asymptomatic[41]. Interestingly, amyloid fibril composition has been shown to affect the result of 99mTc-DPD scintigraphy. Among 55 biopsy-proven TTR patients, all of those with type A fibrils, and none of those with type B, showed tracer uptake. Type B fibrils were associated with early-onset V30M mutation and in patients carrying the Y114C mutation in inherited TTR, whereas type A was noted in all other mutations currently examined as well as in acquired TTR cardiomyopathy[42].

**99mTc-PYP scintigraphy**

99mTc-PYP is currently the most commonly used form of nuclear scintigraphy. There is growing evidence behind its use of as a cardiac tracer in TTR. In a large multicenter study of 171 patients with CA, 121 due to TTR, 99mTc-PYP showed 91% sensitivity and 92% specificity in diagnosing TTR cardiomyopathy[43]. Another study demonstrated the ability of 99mTc-PYP cardiac imaging to distinguish AL from TTR cardiomyopathy with a sensitivity of 97% and specificity of 100% when heart-to-contralateral ratio of > 1.5 was used[44]. Furthermore, 99mTc-PYP scintigraphy showed reduced uptake in the apical segments of the LV in TTR. This correlates with apical sparing of longitudinal strain seen on echocardiography[45].

In addition, there may be potential to diagnose early TTR cardiomyopathy. An observational study of carriers of inherited TTR mutations included 12 asymptomatic carriers with normal echocardiographic and biochemical parameters. Cardiac 99mTc-PYP uptake was abnormal by visual scoring, comparing cardiac to bone tracer uptake, in 84%. Grade 2 or 3 tracer avidity, indicating TTR deposition, was seen in 58%[46]. However, serial 99mTc-PYP scanning has not been shown to track disease progression accurately, as demonstrated in a small study, which showed no significant change in tracer uptake after 18 mo despite obvious clinical progression of disease[47].

**POSITRON EMISSION TOMOGRAPHY**

Radionuclide amyloid ligands have previously been developed to investigate for
Table 1  Perugini visual scoring

| Score | Cardiac uptake and bone uptake                      |
|-------|-----------------------------------------------------|
| Score 0 | Absent cardiac uptake and normal bone uptake       |
| Score 1 | Mild cardiac uptake                                 |
| Score 2 | Moderate cardiac uptake accompanied by attenuated bone uptake |
| Score 3 | Strong cardiac uptake with mild/absent bone uptake    |

amyloid deposits in the brain in Alzheimer’s disease. These tracers have also shown some utility in amyloid cardiomyopathy. Its concomitant use with nuclear scintigraphy aids in confirming localization of tracer uptake in heart. A systematic review of six studies involving the use of positron emission tomography (PET) in amyloid cardiomyopathy, including 98 patients, demonstrated a pooled sensitivity of 95% and specificity of 98% in differentiating amyloid cardiomyopathy from controls\[48\]. Although the individual studies have been small, due to high levels of accuracy, the use of PET and scintigraphy may potentially aid in screening early phases of TTR cardiomyopathy where structural disease may not be apparent on echocardiography or CMR\[49\]. This requires further exploration. Evidence of PET studies utilizing various cardiac tracers are described below.

\[11\]C-Pittsburgh compound B, a radiotracer commonly used in the investigation of Alzheimer’s disease, has the ability to identify amyloid cardiomyopathy due to both type A and type B amyloid fibrils. While this method does not distinguish between TTR and AL, it may help identify certain patients with type B amyloid fibril disease, predominantly V30M mutation-associated TTR cardiomyopathy where \[^{99m}\mathrm{Tc} \text{-DPD}\] scintigraphy has shown a lack of tracer uptake. However, the mechanism of this is not fully known\[42,50\]. In addition, the utility of this compound is limited by its very short half-life and difficult production.

\[18\]F-florbetaben PET has been shown to help identify patients with amyloid cardiomyopathy, due to TTR or AL. Percentage \[^{18}\mathrm{F}\text{-florbetaben}\] retention was shown to predict myocardial dysfunction in amyloid cardiomyopathy\[51\]. In another study of 14 patients, 9 with AL or TTR cardiomyopathy and 5 controls, \[^{18}\mathrm{F}\text{-florbetapir}\] uptake was seen in all patients with amyloid cardiomyopathy and none of the controls\[50\]. An autopsy study of 20 patients with autopsy-documented TTR cardiomyopathy, either due to AL or TTR, and 10 controls, showed binding of \[^{18}\mathrm{F}\text{-florbetapir}\], a similar tracer to \[^{18}\mathrm{F}\text{-florbetaben}\], in myocardial sections in all amyloid cardiomyopathy patients and in none of the controls\[50\].

\[^{18}\mathrm{F}\text{-fluorine sodium fluoride}\] is a PET tracer that has been shown, in a small study, to differentiate biopsy-proven TTR from AL cardiomyopathy and controls. Tracer uptake was shown to be present in all of the TTR cardiomyopathy patients and none of either the AL-related patients or controls\[52\]. This radioisotope was also able to quantify the degree and regional distribution of tracer uptake. However, another report of two patients with TTR cardiomyopathy did not show any uptake of this tracer\[50\]. The authors hypothesized that specific TTR mutation may influence radioisotope uptake. Therefore, while \[^{18}\mathrm{F}\text{-fluorine sodium fluoride}\] shows promise as a TTR-specific investigative and disease-monitoring tool, it requires further investigation in larger studies.

CARDIAC COMPUTED TOMOGRAPHY

Currently, there is limited evidence regarding the utility of computed tomography (CT) in diagnosing TTR cardiomyopathy. Myocardial iodine concentration and ratio were increased in amyloid cardiomyopathy and can accurately distinguish amyloid cardiomyopathy from non-amyloid hypertrophic cardiomyopathy and healthy controls with an AUC of 0.99. At a threshold of 0.65, iodine ratio demonstrated a sensitivity of 100% and a specificity of 92% in diagnosing amyloid cardiomyopathy\[53\]. Myocardial extracellular volume measured using CT has been shown to accurately track laboratory and echocardiographic markers of amyloid cardiomyopathy severity and correlate with bone scintigraphy quantification of amyloid burden\[53\]. Furthermore, determining the myocardial extracellular volume previously required blood sampling to measure haematocrit level. However, recently, a methodology of calculating the extracellular volume, using a calculation involving the attenuation of blood, has eliminated the need for blood sampling from this process. This improves the feasibility of using CT as a potentially useful imaging modality in amyloid...
CARDIAC MAGNETIC RESONANCE

Cardiac magnetic resonance (CMR) is a useful imaging modality in the diagnosis of amyloid cardiomyopathy. Its utility in assessing abnormal myocardial interstitium was described in 2005\(^{[58]}\). Characteristic features seen in amyloid cardiomyopathy were described as a subendocardial tram-line pattern on LGE imaging which can progress to transmural enhancement in later stages of the disease\(^{[59]}\) (Figure 1). Alongside LGE, conventional sequences and non-contrast techniques including native T1 mapping can help diagnose amyloid cardiomyopathy and quantify amyloid burden, although caution should be applied in the setting of ectopic beats, which is not uncommonly associated with amyloid cardiomyopathy, but may result in overlapping blood pool and subsequent false positive diffuse elevation of T1 levels. Cardiac involvement in patients with inherited TTR can be seen in patients without clinical cardiac signs or increased LV wall thickness on CMR, suggesting a potential role in detecting pre-clinical amyloid cardiomyopathy in certain at-risk patients\(^{[60]}\).

LATE GADOLINIUM ENHANCEMENT

LGE on CMR has been shown to be of high diagnostic value in amyloid cardiomyopathy and has achieved a diagnostic sensitivity of 85\% and specificity of 92\% in a meta-analysis of five studies\(^{[61]}\). Transmural pattern of LGE has been shown to be more associated with TTR than AL, although the classically described circumferential subendocardial or transmural LGE is not seen in most patients with amyloid cardiomyopathy. Other findings which are more suggestive of TTR include greater intraventricular septal wall thickness and right ventricular LGE\(^{[62]}\). These investigators also proposed a scoring system, derived from CMR with LGE, which differentiates TTR from AL with 87\% sensitivity and 96\% specificity\(^{[62]}\).

Furthermore, the results of a study by Fontana and colleagues suggested that phase sensitive inversion recovery should replace conventional magnitude inversion recovery for LGE determination in the setting of amyloid cardiomyopathy. Phase sensitive inversion recovery helps to remove the potential confounder of incorrect inversion recovery time selection in diffuse infiltrative disease\(^{[63]}\). Higher proportion of left atrial LGE has been shown to have a strong association with amyloid cardiomyopathy and may help in differentiating amyloid cardiomyopathy from other cardiomyopathies. A sensitivity of 76\% and specificity of 94\% has been shown where left atrial LGE is > 33\%, with significant reduction in left atrial emptying function\(^{[64]}\).

However, LGE has some limitations in the investigation of amyloid cardiomyopathy. LGE does not enable assessment of diffuse changes in interstitial space secondary to amyloid deposition or quantitative assessment of expanded interstitium. This is due to inversion time adjustment to the least-enhancing myocardial region. As a result, absence of LGE does not confirm normal myocardium in amyloid cardiomyopathy\(^{[65]}\). Another limitation associated with gadolinium enhancement is the risk of nephropathy. Caution is warranted due to the high prevalence of renal impairment in patients with amyloid cardiomyopathy.

T1 MAPPING

T1 native mapping using non-contrast MRI has shown high levels of diagnostic accuracy in detecting AL cardiomyopathy. In a study of 53 AL amyloidosis patients, 28 patients with confirmed AL cardiomyopathy were compared to 36 healthy controls and 17 patients with aortic stenosis. Accuracy of 92\% was seen using a non-contrast T1 cut-off of 1020 ms\(^{[66]}\). Compared to TTR cardiomyopathy, T1 elevations are higher in AL cardiomyopathy but similar diagnostic and disease-tracking performance has been shown in TTR. In TTR, T1 also correlates with left atrial area and with PR interval and QRS duration on electrocardiogram\(^{[67]}\). Quantification methods of myocardial T1, such as weighted mean shortened modified look-locker inversion recovery sequence T1 values have been shown to be significantly higher in amyloid cardiomyopathy when compared to healthy controls\(^{[68]}\). T1 mapping allows detection of diffuse myocardial disease and quantitative assessments, which are limited in LGE imaging\(^{[69]}\).

T1 mapping can accurately identify patients with LGE-confirmed cardiac involvement in TTR and correlates well with the degree of amyloid deposition\(^{[69]}\). As a
Cardiac magnetic resonance. A, B: Cardiac magnetic resonance demonstrating diffuse, circumferential and near transmural late gadolinium enhancement of the left ventricle in the 4-chamber (A) and short axis views (B), features which are characteristic of amyloid cardiomyopathy.

result, it can help improve detection rates of amyloid cardiomyopathy when used in combination with LGE sequences. It is also a particularly useful tool when contrast is contraindicated due to renal impairment and when LGE artefacts occur due to poor breath-holding and arrhythmias; diagnostic problems commonly seen in these patients.

MYOCARDIAL EXTRACELLULAR VOLUME

Myocardial extracellular volume is another cardiac mapping technique using CMR that is a validated indicator of myocardial fibrosis[70]. It involves T1 mapping acquisitions before and after T1-shortening contrast injection. Both T1 mapping and extracellular volume have recently been shown to perform well as diagnostic techniques in differentiating TTR from other causes of hypertrophic cardiomyopathy[71]. While not a specific feature of amyloid cardiomyopathy, it has been identified as a potential disease-marker to track therapeutic response in the reduction of hepatic amyloid burden following the use of anti-serum amyloid P component antibody in systemic amyloidosis[72].

Extracellular volume correlates with amyloid burden and has been shown to be an independent prognostic factor for survival in TTR cardiomyopathy patients[73]. Furthermore, extracellular volume has been suggested as a more robust marker in TTR cardiomyopathy when compared to T1 mapping as it has shown independent prediction of mortality, where T1 mapping has not[71]. In this regard, T1 mapping and extracellular volume are divergent when comparing TTR to AL cardiomyopathy. Extracellular volume is higher in TTR, reflecting proportionally more amyloid deposition. In contrast, native T1 levels, reflecting both interstitial and cellular changes, are lower in TTR[74]. However, these differing myocardial observations are poorly understood.

OTHER SEQUENCES

CMR-measured longitudinal strain can demonstrate the relative apical sparing and base-to-apex gradient in longitudinal strain, with significantly reduced global longitudinal strain, which is characteristic of amyloid cardiomyopathy[75]. Strain analysis using CMR can help diagnose LGE-positive amyloid cardiomyopathy patients while avoiding the need for contrast medium. Peak circumferential strain level and variability may be more sensitive when compared to LGE imaging in detecting early cardiac involvement in amyloid cardiomyopathy[76]. Basal segments strain parameters can accurately identify cardiac involvement in patients with amyloidosis[76].

Operator-independent heart deformation analysis using CMR has been shown to accurately reproduce radial and circumferential regional myocardial motion patterns, which correlate with feature-tracking indices in amyloid cardiomyopathy[70].

Reduced T2 ratio, comparing the T2 signal intensity of myocardium to skeletal muscle, has shown some utility in amyloid cardiomyopathy diagnosis and can predict mortality[79]. Myocardial oedema, as assessed by T2 mapping, is elevated in both TTR and AL cardiomyopathy, although to a higher degree in AL[80].
CONCLUSION

The use of multi-modality imaging in the diagnosis and management of suspected TTR cardiomyopathy is becoming increasingly accurate and necessary. In light of recent evidence for disease-specific therapeutic agents, high clinical suspicion coupled with earlier utilization of non-invasive imaging modalities are essential for diagnosing this insidious and elusive disease.

REFERENCES

1. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012; 126: 1286-1300 [PMID: 22949559 DOI: 10.1161/CIRCULATIONAHA.111.078915]

2. Dugan J, Sattianayagam PT, Whelan CJ, Gibbs SD, Pinney JH, Banzragd SM, Rowczenio D, Gilbertson JA, Lachmann JH, Wechalekar A, Gillmore JD, Hawkins PN, Anderson LJ. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J 2012; 164: 72-79 [PMID: 22795285 DOI: 10.1016/j.ahj.2012.04.013]

3. Gillmore JD, Darby T, Fontana M, Hutchinson M, Lachmann JH, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018; 39: 2799-2806 [PMID: 29048471 DOI: 10.1093/eurheartj/ehz589]

4. Kelley WE, Januzzi JL, Christenson RH. Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. Clin Chem 2009; 55: 2098-2112 [PMID: 19815160 DOI: 10.1373/clinchem.2009.037099]

5. Ardehali H, Qasim A, Cappola T, Howard D, Hruban R, Hare JM, Baughman KL, Kasper EK. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J 2004; 147: 919-923 [PMID: 15131552 DOI: 10.1016/j.ahj.2003.09.020]

6. Longhi S, Guidalotti PL, Quarta CC, Gagliardi C, Milandri A, Lorenzini M, Potena L, Leone O, Bartolomei I, Pastorelli F, Salvi F, Rapezzi C. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovascular Imaging 2014; 7: 531-532 [PMID: 24831216 DOI: 10.1016/j.jcmg.2013.03.004]

7. Costa A, Narotsky DJ, Hamid N, Khalique OK, Morgensen R, Deluca A, Rubin J, Chuzan C, Nazif T, Vahl T, George J, Kolidi S, Leon MB, Hahn R, Bokhari S, Maurer MS. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017; 38: 2879-2887 [PMID: 29019612 DOI: 10.1093/eurheartj/ehx230]

8. Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, Roberts N, Huff DF, Rowczenio DM, Whelan CJ, Ashworth MA, Gilmore JD, Hawkins PN, Moon JC. Occult Transthyretin Cardiac Amyloidosis in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement. Circ Cardiovasc Imaging 2016; 9 [PMID: 27511799 DOI: 10.1161/CIRCIMAGING.116.005960]

9. Danny T, Costes B, Hagège AA, Donal E, Eicher JC, Slama M, Gueuiller A, Rappeneau S, Schuit P, Lefort S, Huet D, Gilbertson JA, Lachmann JH, Hawkins PN, Anderson LJ, Goossens M, Canou-Poitrine F, Buxbaum JN. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur J Heart J 2016; 37: 1826-1834 [PMID: 26537620 DOI: 10.1093/eurheartj/ehv583]

10. Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Mezzello G, de Haro-DEL Moral FJ, Cobos Marcos M, Robles C, Bornstein IB, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P, Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36: 2585-2594 [PMID: 26224076 DOI: 10.1093/eurheartj/ehv335]

11. Bennani Smail Y, Victor G, Ribes D, Berry M, Cognet T, Méjean S, Huart A, Roussel M, Petermann A, Carvalho A, Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: issues and challenges. J Hepatol 2008; 49: 232-239 [PMID: 18382889 DOI: 10.1016/j.jhep.2007.09.020]

12. Tanskanen M, Peuralinna T, Polvikoski T, Nokkala L, Sulkava R, Hardy J, Singleton A, Kuoro-Enari S, Paetau A, Tienari PJ, Myllýkangas L. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 2008; 40: 232-239 [PMID: 18382889 DOI: 10.1080/0785389070184298]

13. Carvalho A, Rocha A, Lobato L. Liver transplantation in amyloidosis: issues and challenges. Liver Transplant 2015; 21: 282-292 [PMID: 25482846 DOI: 10.1002/lt.24059]

14. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Hutt DF, Rowczenio D, Darby T, Damy T, Drachman BM, Shah SJ, Hare JM, Hruban R, Hare JM, Moller A, Mezei MM, Campistol JM, Buades J, Brannagan TH, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polyedekis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nocher SV, Sweeter MP, Garg PV, Vaishnav A, Godbold JA, Suhr OB. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med 2018; 379: 11-21 [PMID: 29972753 DOI: 10.1056/NEJMoa1716153]

15. Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Krishna AV, Tournei S, Schmid HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezi MM, Campistol JM, Buades J, Brannagan TH, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polyedekis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nocher SV, Sweeter MP, Garg PV, Vaishnav A, Godbold JA, Suhr OB. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med 2018; 379: 11-21 [PMID: 29972753 DOI: 10.1056/NEJMoa1716153]

16. Keshane D, Schwartz J, Gundapaneni B, Stewart M, Amass L. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid 2017; 24: 30-36 [PMID: 28395570 DOI: 10.1080/13506129.2017.1301419]

17. Castaño A, Drachman BM, Judge D, Maurer MS, Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev 2015; 20: 163-178 [PMID: 25408161 DOI: 10.1007/s10741-014-9462-7]
Tc-DPD in patients with hereditary transthyretin-related cardiac amyloidosis. 99mHMDP vs J Nucl Cardiol
Dubois-Randé JL, Bodez D, Rosso J, Damy T, Itti E. Early-phase myocardial uptake intensity of, Cottereau AS, Guellich A, Vandeventer S, Galat A, Van Der Gucht A, Plante-Bordeneuve V, Abulizi M: 1183-1190 [PMID: 28256403 DOI: 10.1016/j.hlc.2016.12.017]
Heart Lung Circ Scintigraphy in the Diagnosis of Cardiac Amyloidosis: An Australian Experience. , Burrage MK, Mackenzie E, Law WP, Korczyk D, Mollee P. The Utility of 24 2011; Imaging Eur J Nucl Med Mol acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Gagliardi C, Branzi A. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. 2014; J Am Coll Cardiol Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C. Noninvasive etiologic diagnosis of cardiac amyloidosis. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Gillmore JD, Hawkins PN, Wechalekar AD. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. 28298286 DOI: 10.1161/CIRCIMAGING.116.005588
Minamisawa M, Koyama I, Sekijima Y, Ikeda S, Kozuka A, Ebisawa S, Miura T, Motoki H, Okada A, Iizawa A, Ikeda U. Comparison of the standard and speckle tracking echocardiographic features of wild-type and mutated transthyretin cardiac amyloidoses. Eur Heart J Cardiovasc Imaging 2016; 17: 402-410 [PMID: 26873458 DOI: 10.1036/j.ehjci.0072]
Nochioka K, Quarta CC, Caggetti B, Rocca GQ, Rapediz C, Falk RH, Solomon SD. Left atrial structure and function in cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 2017; 18: 1128-1137 [PMID: 28637305 DOI: 10.1036/j.ehjci.097]
Kado Y, Obokata M, Nagata Y, Ishizu T, Addetia K, Aonuma K, Kurabayashi M, Lang RM, Takeuchi M, Otsuji Y. Cumulative Burden of Myocardial Dysfunction in Dysfunction in Cardiac Amyloidoses Assessed Using Four-Chamber Cardiac Strain. J Am Soc Echocardiogr 2016; 29: 1092-1099.e2 [PMID: 27614542 DOI: 10.1016/j.echo.2016.07.017]
Senapati A, Sperry BW, Grodin JL, Kusnose K, Thavendiranathan P, Jaber W, Collier P, Hanna M, Popovic ZB, Phelan D. Prognostic implication of relative regional strain ratio in cardiac amyloidosis. Heart 2016; 102: 748-754 [PMID: 26830665 DOI: 10.1136/heartjnl-2015-308657]
Bodez D, Ternacle J, Guellich A, Galat A, Lins P, Radu C, Guendouz S, Bergoend E, Courtet JP, Hittinger L, Dubois-Rande JL, Plante-Bordeneuve V, Deux JF, Mohty D, Damy T. Prognostic value of right ventricular systolic function in cardiac amyloidosis. Amyloid 2016; 23: 158-167 [PMID: 27348696 DOI: 10.1080/10506129.2016.1194264]
Patel AR, Dubrey SW, Mendes LA, Skinner M, Cupples A, Falk RH, Davidoff R. Right ventricular dilation in primary amyloidosis: an independent predictor of survival. Am J Cardiol 1997; 80: 486-492 [PMID: 9285663 DOI: 10.1016/S0002-9149(97)00400-1]
VanAntwerp JD, O'Mara RE, Pitt MJ, Walsh S. Technetium-99m-diphosphonate accumulation in amyloid. J Nucl Med 1975; 16: 238-240 [PMID: 1113174]
Stath MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidoses: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol 2016; 25: 413-417 [PMID: 27469499 DOI: 10.1016/j.carpath.2016.07.001]
Gillmore JD, Maurer MS, Falk RH, Merlino G, Dany J, Dispenceria A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Gladeins AW, Zek T, Fontana M, Palladini G, Milan P, Guidalotti PL, Flattman K, Lane T, Von Borg W, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Prognostic Diagnosis of G3Tm-3,3-Diphosphono-1,2-Propanodicarboxylic Acid (Tnpa) Scintigraphy in Transthyretin Amyloidosis. Circulation 2016; 133: 2404-2412 [PMID: 27143678 DOI: 10.1161/CIRCULATIONAHA.116.021612]
Hutt DF, Fontana M, Burniston J, Quigley AM, Petrie A, Ross JC, Page J, Martinez-Naharro A, Wechalekar AD, Lachmann HJ, Quarta CC, Zek T, Mahmood S, Szechinskiwonsan S, Yagounrin T, Whelan CJ, Lane T, Gilbertson JA, Rowenchten D, Hawkins PN, Gillmore JD. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging 2017; 18: 1344-1350 [PMID: 28159995 DOI: 10.1093/ehjci/jex325]
Harb SC, Haq M, Flood K, Guerrieri A, Passerell W, Jaber WA, Miller EJ. National patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m- pyrophosphate scintigraphy. J Nucl Cardiol 2017; 24: 1094-1097 [PMID: 27061106 DOI: 10.1007/s01235-016-0478-3]
Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, Lane T, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD. Utility and limitations of 3,3-diphenyl-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging 2014: 15: 1289-1298 [PMID: 24939945 DOI: 10.1093/ehjci/jet107]
Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphenyl-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005; 46: 1076-1084 [PMID: 16168294 DOI: 10.1016/j.jacc.2004.09.037]
Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, Ferlini A, Salvi F, Gallo P, Gagliardi C, Branzi A. Usefulness and limitations of 99mTc-3,3-diphenyl-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011; 38: 470-476 [PMID: 21095320 DOI: 10.1007/s00259-010-1642-7]
Moore PT, Burage MK, Mackenzie E, Law WP, Korczyk D, Moller P. The Utility of 99mTc-DPD Scintigraphy in the Diagnosis of Cardiac Amyloidosis: An Australian Experience. Heart Lung Circ 2017; 26: 1183-1190 [PMID: 28225403 DOI: 10.1016/j.hlc.2016.12.017]
Abuzli M, Cotteraeus AS, Guellich A, Vandevoenter S, Galat A, Van Der Gucht A, Plante-Bordeneuve V, Dubois-Rande JL, Bodez D, Rosso J, Dany T, Itri E. Early-phase myocardial uptake intensity of 99mTc-HMDP vs 99mTc-DPD in patients with hereditary transthyretin-related cardiac amyloidosis. J Nucl Cardiol
A, Gillmore JD, Whelan CJ, Hawkins PN, Anderson LJ. CMR-based differentiation of AL and ATTR suspected cardiac amyloidosis: a systematic review and meta-analysis. *JAMA Cardiol* 2016; 1: 880-889 [PMID: 27557406 DOI: 10.1001/jamacardio.2016.2839]

Bokhari S, Castaño A, Pozniakoff T, Desilisse S, Latif F, Maurer MS, (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. *Circ Cardiovasc Imaging* 2013; 6: 195-201 [PMID: 23408849 DOI: 10.1161/CIRCIMAGING.112.000132]

Sperry BW, Vranian MN, Tower-Rader A, Hachamovitch R, Hanna M, Brunken R, Phelan D, Cerqueira MD, Jaber WA. Regional Variation in Technetium Pyrophosphate Uptake in Transthyretin Cardiac Amyloidosis and Impact on Mortality. *JACC Cardiovascular Imaging* 2018; 11: 234-242 [PMID: 28917675 DOI: 10.1016/j.jcmg.2017.06.020]

Haq M, Pawar S, Berk JL, Miller EJ, Ruberg FL. Can 99mTc-Pyrophosphate Absent in Early Detection of Cardiac Involvement in Asymptomatic Variant TTR Amyloidosis? *JACC Cardiovascular Imaging* 2017; 10: 713-714 [PMID: 27560122 DOI: 10.1016/j.jcim.2016.06.003]

Castaño A, DeLuca A, Weinberg R, Pozniakoff T, Blanter WS, Pirmohamed A, Bettencourt B, Gollob J, Karsten V, Vest JA, Chizian C, Maurer MS, Bokhari S. Serial scanning with technetium pyrophosphate (99mTc-fPP) in advanced ATTR cardiac amyloidosis. *J Nucl Cardiol* 2016; 23: 1355-1363 [PMID: 26453570 DOI: 10.1007/s12350-015-0261-x]

Kim YJ, Ha S, Kim YJ. Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis. *J Nucl Cardiol* 2018; 25: 240-248 [PMID: 27645889 DOI: 10.1007/s12350-018-0365-8]

Dorbala S, Vangala D, Semer J, Strader C, Broyere JR, Di Carlo MF, Moore SC, Falk RH. Imaging cardiac amyloidosis: a pilot study using 18F-florbetapit positron emission tomography. *Eur J Nucl Med Mol Imaging* 2014; 41: 1652-1662 [PMID: 24841414 DOI: 10.1007/s00259-014-2787-6]

Pilebro B, Arvidsson S, Lindqvist P, Sundström T, Westermark P, Antoni G, Suhr O, Sörensen J. Positron emission tomography (PET) utilizing Pittsburgh compound B (Pb) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR). *J Cardiovasc Comput Tomogr* 2015; 28: 240-248 [PMID: 27657428 DOI: 10.1007/s12350-015-0457-8]

Law WP, Wang WY, Moore PT, Mollee PN, Ng AC. Cardiac Amyloid Imaging with 18F-Florbetaben PET: A Pilot Study. *J Nucl Med* 2015; 56: 1733-1739 [PMID: 27307344 DOI: 10.2986/jnmed.115.169870]

Park MA, Padera RF, Belanger A, Dubey S, Hwang DH, Veevarana V, Falk RH, Di Carlo MF, Dorbala S. 18F-Florbetapit Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study. *Circ Cardiovasc Imaging* 2015; 8 [PMID: 26259579 DOI: 10.1161/CIRCIMA GING.114.002954]

Morgenstern R, Yeh R, Castaño A, Maurer MS, Bokhari S. 18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. *J Nucl Cardiol* 2018; 25: 1559-1567 [PMID: 28176254 DOI: 10.1007/s12350-017-0799-x]

Gagliardi C, Tabacchi E, Bonfiglioli R, Diodato S, Nanni C, Guidalotti P, Lorenzini M, Lodi F, Milandri A, Rapezzi C, Fanti S. Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT? *J Nucl Cardiol* 2017; 24: 746-749 [PMID: 26976144 DOI: 10.1007/s12350-016-0457-8]

Chevannes V, Damy T, Tacher V, Legou F, Roudaut R, Chariot P, Luciani C, Fournier A. Myocardial iodine concentration measurement using dual-energy computed tomography for the diagnosis of cardiac amyloidosis: a pilot study. *Eur Radiol* 2018; 28: 816-823 [PMID: 28812126 DOI: 10.1007/s00259-017-6948-8]

Treibel TA, Bandula S, Fontana M, White SK, Gilbertson JA, Herrey AS, Gillmore JD, Punwani S, Hawkins PN, Taylor SA, Moon JC. Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. *J Cardiovasc Comput Tomogr* 2015; 9: 585-592 [PMID: 26209459 DOI: 10.1016/j.jcct.2015.07.001]

Treibel TA, Fontana M, Steeden JA, Nais J, Yeung J, White SK, Sivarajan S, Punwani S, Pugliese F, Taylor SA, Moon JC, Bandula S. Automatic quantification of the myocardial extracellular volume by cardiac computed tomography: Synthetic ECV by CCT. *J Cardiovasc Comput Tomogr* 2017; 11: 221-226 [PMID: 28268091 DOI: 10.1016/j.jcct.2017.02.006]

Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ. Cardiovascular magnetic resonance in cardiac amyloidosis. *Circulation* 2005; 111: 186-193 [PMID: 15630027 DOI: 10.1161/01.CIR.0000152919.92767.90]

Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, Mascherbauer J, Nezafat R, Salerno M, Schelbert EB, Taylor AJ, Thompson R, Ugander M, van Heeswijk RB, Friedrich MG. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). *J Cardiovasc Magn Reson* 2017; 19: 75 [PMID: 28992817 DOI: 10.1186/s12968-017-0389-4]

Deux JF, Damy T, Rahmouni A, Mayer J, Planté-Bordeneuve V. Noninvasive detection of cardiac involvement in patients with hereditary transthyretin associated amyloidosis using cardiac magnetic resonance imaging: a prospective study. *Amyloid* 2014; 21: 246-255 [PMID: 25211144 DOI: 10.3109/13506129.2014.956934]

Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. *BMC Cardiovasc Disord* 2016; 16: 129 [PMID: 27267362 DOI: 10.1186/s12872-016-0311-6]
cardiac amyloidosis. *JACC Cardiovasc Imaging* 2014; 7: 133-142 [PMID: 24412186 DOI: 10.1016/j.jcmg.2013.08.015]

63 Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibl TA, Banyersad SM, Maestri V, Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Manhood S, Bucciarelli-Ducci C, Whelan CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schellert EB, Kellman P, Gillmore JD, Hawkins PN, Moon JC. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. *Circulation* 2015; 132: 1570-1579 [PMID: 26362631 DOI: 10.1161/CIRCULATIONAHA.115.016567]

64 Kwong RY, Heydari B, Abbasi S, Steel K, Al-Mallah M, Wu H, Falk RH. Characterization of Cardiac Amyloidosis by Atrial Late Gadolinium Enhancement Using Contrast-Enhanced Cardiac Magnetic Resonance Imaging and Correlation With Left Atrial Conduit and Contractile Function. *Am J Cardiol* 2015; 116: 622-629 [PMID: 26070990 DOI: 10.1016/j.amjcard.2015.05.021]

65 Hashimura H, Kimura F, Ishibashi-Ueda H, Morita Y, Higashi M, Nakano S, Iiguchi A, Uotani K, Sugimura K, Naito H. Radiologic-Pathologic Correlation of Primary and Secondary Cardiomyopathies: MR Imaging and Histopathologic Findings in Hearts from Autopsy and Transplantation. *Radiographics* 2017; 37: 719-736 [PMID: 28129067 DOI: 10.1148/rg.17116088]

66 Karamitso T, Piekchn SK, Banyersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. *JACC Cardiovasc Imaging* 2013; 6: 488-497 [PMID: 23498672 DOI: 10.1016/j.jcim.2012.11.013]

67 Fontana M, Banyersad SM, Treibl TA, Maestri V, Sado DM, White SK, Pica S, Castelletti S, Piekchn SK, Robson MD, Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ, Wechalekar AD, Whelan CJ, Gillmore JD, Hawkins PN, Moon JC. Native T1 mapping in transthyretin amyloidosis. *JACC Cardiovasc Imaging* 2014; 7: 157-165 [PMID: 24412190 DOI: 10.1016/j.jcmg.2013.10.008]

68 van den Boomen M, Slart RHJ, Huuleman EV, Diercks RAJO, Veltbus IK, van der Harst P, Sosnovik DE, Borra RJL, Prakken NHJ. Native T1 reference values for nons ischemic cardiomyopathies and populations with increased cardiovascular risk: A systematic review and meta-analysis. *J Magn Reson Imaging* 2018; 47: 891-912 [PMID: 29131446 DOI: 10.1002/jmri.25885]

69 Oda S, Utsumoiyoda M, Morita K, Nakauro T, Yuki H, Kido Y, Hirata T, Tsuchi Y, Nakauro T, Ueda M, Yamashita T, Ando Y, Yamashita Y. Cardiovascular magnetic resonance myocardial T1 mapping to detect and quantify cardiac involvement in familial amyloid polyneuropathy. *Eur Radiol* 2017; 27: 4631-4638 [PMID: 28477167 DOI: 10.1007/s00330-017-4845-5]

70 Miller CA, Naish JH, Bishop P, Couts G, Clark D, Zhao S, Ray SG, Yonan N, Williams SG, Flitt AS, Moon JC, Greiser A, Parker GI, Schmitt M. Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. *Circ Cardiovasc Imaging* 2013; 6: 373-383 [PMID: 23553570 DOI: 10.1161/CIRCIMAGING.112.000192]

71 Martinez-Naharro A, Kotecha T, Norrington K, Boldini M, Rezk T, Quarta C, Treibl TA, Whelan CJ, Knight DS, Kellman P, Ruberg FL, Gillmore JD, Moon JC, Hawkins PN, Fontana M. Native T1 and Extracellular Volume in Transthyretin Amyloidosis. *JACC Cardiovasc Imaging* 2019; 12: 810-819 [PMID: 29580234 DOI: 10.1016/j.jcmg.2018.02.006]

72 Richards DB, Cookson LM, Berge AC, Barton SV, Lane T, Ritter JM, Fontana M, Moon JC, Pinzani M, Gillmore JD, Hawkins PN, Pepys MB. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. *N Engl J Med* 2015; 373: 1106-1114 [PMID: 26176329 DOI: 10.1056/NEJMoa1504942]

73 Martinez-Naharro A, Treibl TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, Kellman P, Gillmore JD, Hawkins PN, Fontana M. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. *J Am Coll Cardiol* 2017; 60: 466-477 [PMID: 28728692 DOI: 10.1016/j.jacc.2017.05.053]

74 Fontana M, Banyersad SM, Treibl TA, Maestri V, Sado D, White SK, Bulluck H, Herrey AS, Hawkins PN, Moon JC. AL and ATTR cardiac amyloid are different: native T1 mapping and ECV detect different biology. *J Cardiovasc Magn Reson* 2013; 16: P341 [DOI: 10.1186/1532-429X-16-S1-P341]

75 Hawkins PN, Moon JC, Pepys MB. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. *N Engl J Med* 2015; 373: 1106-1114 [PMID: 26176329 DOI: 10.1056/NEJMoa1504942]

76 Williams LF, Forero JR, Popovic ZB, Phelan D, Delgado D, Rakowski H, Wintersperger BJ, Thavendiranathan P. Patterns of CMR measured longitudinal strain and its association with late gadolinium enhancement in patients with cardiac amyloidosis and its mimics. *J Cardiovasc Magn Reson* 2017; 19: 61 [PMID: 28784140 DOI: 10.1186/s12968-017-0376-0]

77 Oda S, Utsumoiyoda M, Nakauro T, Yuki H, Kidoh M, Hirata T, Taguchi N, Tsuda N, Shiraiishi S, Namimoto T, Hirakawa K, Takashio S, Izuimiyama M, Yamamuro M, Hokimoto S, Tsujita K, Ueda M, Yamashita T, Ando Y, Yamashita Y. Cardiovascular magnetic resonance myocardial T1 mapping to detect and quantify cardiac involvement in familial amyloid polyneuropathy. *Eur Radiol* 2017; 27: 4631-4638 [PMID: 28477167 DOI: 10.1007/s00330-017-4845-5]

78 Miller CA, Naish JH, Bishop P, Couts G, Clark D, Zhao S, Ray SG, Yonan N, Williams SG, Flitt AS, Moon JC, Greiser A, Parker GI, Schmitt M. Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. *Circ Cardiovasc Imaging* 2013; 6: 373-383 [PMID: 23553570 DOI: 10.1161/CIRCIMAGING.112.000192]

79 Martinez-Naharro A, Kotecha T, Norrington K, Boldini M, Rezk T, Quarta C, Treibl TA, Whelan CJ, Knight DS, Kellman P, Ruberg FL, Gillmore JD, Moon JC, Hawkins PN, Fontana M. Native T1 and Extracellular Volume in Transthyretin Amyloidosis. *JACC Cardiovasc Imaging* 2019; 12: 810-819 [PMID: 29580234 DOI: 10.1016/j.jcmg.2018.02.006]

80 Richards DB, Cookson LM, Berge AC, Barton SV, Lane T, Ritter JM, Fontana M, Moon JC, Pinzani M, Gillmore JD, Hawkins PN, Pepys MB. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. *N Engl J Med* 2015; 373: 1106-1114 [PMID: 26176329 DOI: 10.1056/NEJMoa1504942]
